drugset
drugset / Trial / NCT05978739

Evaluating Different Doses of Orelabrutinib in MCL

NCT05978739 ↗

Phase 2 Completed 40 enrolled InnoCare Pharma Inc. Beijing InnoCare Pharma Tech Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is A Randomized,Open-label, Multicenter, Phase II Trial Evaluating Two Different Doses of Orelabrutinib in Mantle Cell Lymphoma to Evaluate the Efficacy and Safety in Mantle Cell Lymphoma.

Timeline

Start
2023-08-18
Primary completion
2024-12-10
Completion
2024-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Orelabrutinib Small molecule — —

Indications

mantle cell lymphoma